Equifax's analyst price target has decreased from $280.50 to $277.70, as analysts note heightened industry headwinds and ongoing uncertainty following recent market and regulatory developments.
Analyst Commentary
Recent research reports highlight both opportunities and challenges for Equifax, as analysts adjust price targets and revisit expectations in light of evolving industry conditions and company-specific developments.
Bullish Takeaways- Bullish analysts maintain positive ratings following Q2 results. They note current share price levels may represent an attractive entry point for long-term investors.
- Despite macroeconomic uncertainties, management upheld guidance excluding foreign exchange impacts. This signals confidence in the company’s core business trajectory.
- Some analysts point to Equifax’s ability to act strategically in response to industry disruption. This could minimize revenue erosion and support future growth.
- Several analysts are lowering price targets, citing headwinds from increased transparency in the mortgage credit process and new competitive pressures.
- Guidance reflects expectations for slower growth in key segments, such as Workforce Solutions and government, particularly in the second half of the year.
- Bearish analysts have reduced their future earnings and EBITDA estimates amid revised outlooks for mortgage volume and sustained regulatory uncertainty.
- Lending-driven upside from recent quarters has not materialized into higher guidance, which tempers near-term growth optimism.
What's in the News
- Klarna and Afterpay announced they will withhold the majority of their "buy now, pay later" loan data from credit bureaus until customers are assured they will not be unfairly penalized. This move highlights tension in how new credit products are factored into credit scores (The Wall Street Journal).
- Equifax launched Identity Proofing in its Kount 360 fraud prevention platform, offering new ID verification and biometric features to help businesses combat rising synthetic identity and deepfake fraud threats.
- Empeon, a healthcare technology company, integrated The Work Number from Equifax to provide automated income and employment verifications. The goal is to simplify processes for employees and healthcare providers.
- Equifax raised full-year 2025 earnings guidance and now projects reported revenue between $5.97 billion and $6.04 billion.
Valuation Changes
- Consensus Analyst Price Target has decreased from $280.50 to $277.70, reflecting a modest reduction.
- Discount Rate has risen slightly from 7.28% to 7.30%.
- Revenue Growth projections have increased from 9.90% to 10.13%.
- Net Profit Margin is up marginally from 16.84% to 16.88%.
- Future P/E ratio has declined from 32.62x to 32.05x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.